Art. 32 Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 42×
1.

When reference is made to the procedure laid down in this Article, the Committee shall consider the matter concerned and shall issue a reasoned opinion within 60 days of the date on which the matter was referred to it.

However, in cases submitted to the Committee in accordance with Articles 30 and 31, this period may be extended by the Committee for a further period of up to 90 days, taking into account the views of the applicants or the marketing authorisation holders concerned.

In an emergency, and on a proposal from its Chairman, the Committee may agree to a shorter deadline.

2.

In order to consider the matter, the Committee shall appoint one of its members to act as rapporteur. The Committee may also appoint individual experts to advise it on specific questions. When appointing experts, the Committee shall define their tasks and specify the time-limit for the completion of these tasks.

3.

Before issuing its opinion, the Committee shall provide the applicant or the marketing authorisation holder with an opportunity to present written or oral explanations within a time limit which it shall specify.

The opinion of the Committee shall be accompanied by a draft summary of product characteristics for the product and a draft text of the labelling and package leaflet.

If necessary, the Committee may call upon any other person to provide information relating to the matter before it.

The Committee may suspend the time-limits referred to in paragraph 1 in order to allow the applicant or the marketing authorisation holder to prepare explanations.

4.

The Agency shall forthwith inform the applicant or the marketing authorisation holder where the opinion of the Committee is that:

(a)

the application does not satisfy the criteria for authorisation; or

(b)

the summary of the product characteristics proposed by the applicant or the marketing authorisation holder in accordance with Article 11 should be amended; or

(c)

the authorisation should be granted subject to certain conditions, in view of conditions considered essential for the safe and effective use of the medicinal product including pharmacovigilance; or

(d)

a marketing authorisation should be suspended, varied or revoked.

Within 15 days after receipt of the opinion, the applicant or the marketing authorisation holder may notify the Agency in writing of his intention to request a re-examination of the opinion. In that case, he shall forward to the Agency the detailed grounds for the request within 60 days after receipt of the opinion.

Within 60 days following receipt of the grounds for the request, the Committee shall re-examine its opinion in accordance with the fourth subparagraph of Article 62(1) of Regulation (EC) No 726/2004. The reasons for the conclusion reached shall be annexed to the assessment report referred to in paragraph 5 of this Article.

5.

Within 15 days after its adoption, the Agency shall forward the final opinion of the Committee to the Member States, to the Commission and to the applicant or the marketing authorisation holder, together with a report describing the assessment of the medicinal product and stating the reasons for its conclusions.

In the event of an opinion in favour of granting or maintaining an authorisation to place the medicinal product concerned on the market, the following documents shall be annexed to the opinion:

(a)

a draft summary of the product characteristics, as referred to in Article 11;

(b)

any conditions affecting the authorisation within the meaning of paragraph 4(c);

(c)

details of any recommended conditions or restrictions with regard to the safe and effective use of the medicinal product;

(d)

the proposed text of the labelling and leaflet.

The 10 that are cited most themselves, of 42.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…16Law

    … посочени в член 8, параграф 3, в членове 10, 10а, 10б и 11 или в член 32, параграф 5 от Директива 2001/83/ЕО, в приложение I към нея или в член 9, …

  • Directive (EU) 2004/27Lawamends

  • Judgment of the Court (First Chamber) of 16 October 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DepartmenDecision

    In the course of those proceedings, the H igh Court of Justice of England and Wales, Queen’s Bench Division (Administrative Court) decided to stay the proceedings and refer the following questions to the Court for a preliminary …

    16 Oct 2008 · 62006CJ0452

  • Arrêt du Tribunal (cinquième chambre) du 11 décembre 2014. PP Nature-Balance Lizenz GmbH contre Commission européenne.Decision

    Am 12. Juli 2012 ersuchten die Gedeon Richter Plc und die Klägerin gemäß Art. 32 Abs. 4 der Richtlinie 2001/83 in geänderter Fassung um Überprüfung des ersten Gutachtens des Ausschusses in Bezug auf die Ergebnisse zur lokomotorischen …

    11 Dec 2014 · 62013TJ0189

  • Geneesmiddelenwet55Law

    1. De artikelen 44, derde, vierde en vijfde lid, en 46, derde en vierde lid, van deze wet alsmede de artikelen 32, 33 en 34 van richtlijn 2001/83 zijn niet van toepassing op kruidengeneesmiddelen als bedoeld in artikel 42, achtste lid, …

  • Gesetz über den Verkehr mit Arzneimitteln25b63cLaw

    … (5) Bei einer abweichenden Entscheidung bezüglich der Zulassung, ihrer Aussetzung oder Rücknahme finden die Artikel 30, 32, 33 und 34 der Richtlinie 2001/83/EG Anwendung. Im Falle einer Entscheidung nach Artikel 34 der Richtlinie …

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…29Law

    … може да бъде подадено в съответствие с процедурата, установена в членове 32, 33 и 34 от Директива 2001/83/ЕО, когато се иска разрешително …

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…1Law

    … посочени в член 8, параграф 3, в членове 10, 10а, 10б и 11 или в член 32, параграф 5 от Директива 2001/83/ЕО, в приложение I към нея или в член 9, …

  • Regeling Geneesmiddelenwet3.5aLaw

    … Als de Commissie ter afsluiting van de arbitrageprocedure, bedoeld in de artikelen 32, 33 en 34 van richtlijn 2001/83, een eindbeschikking heeft vastgesteld neemt het College artikel 34, derde lid, in acht.

  • Règlement grand-ducal du 15 décembre 1992 relatif à la mise sur le marché des médicaments.7Law

    … ou des documents visés à l’article 1er, aux articles 1.-1, 1.-2, 1.-3 et 2, ou à l’avis final visé à l’article 32, paragraphe 5 de la directive modifiée 2001/83/CE du Parlement européen et du Conseil du 6 novembre 2001 …